Key result
Treatment with GP IIb/IIIa inhibitors in AMI patients significantly increased the risk of alveolar hemorrhage compared to untreated controls (0.20% vs 0.025%; P=0.017).
Why the study?
Does treatment with glycoprotein IIb/IIIa inhibitors increase the risk of alveolar hemorrhage in AMI patients receiving coronary arteriography?
Population
9,594 acute myocardial infarction (AMI) patients receiving coronary arteriography
Comparison
Glycoprotein IIb/IIIa inhibitors vs No glycoprotein IIb/IIIa inhibitors
Design
Cohort
Authors
Loading...
May warrant monitoring for alveolar hemorrhage with GP IIb/IIIa inhibitors in AMI; leaves open need for prospective confirmation.
Cohort (n=9,594)
Does treatment with glycoprotein IIb/IIIa inhibitors increase the risk of alveolar hemorrhage in AMI patients receiving coronary arteriography?
Absolute Event Rate: 0.2% vs 0.025%
p-value: p=0.017
Treatment with glycoprotein IIb/IIIa inhibitors, particularly eptifibatide, is associated with a rare but significantly increased risk of alveolar hemorrhage in AMI patients.
Iskandar et al. (2006) conducted a cohort in Acute myocardial infarction (AMI) (n=9,594). Glycoprotein IIb/IIIa inhibitors (eptifibatide or abciximab) vs. No GP IIb/IIIa inhibitors was evaluated on Alveolar hemorrhage (AH) (p=0.017). Treatment with GP IIb/IIIa inhibitors in AMI patients significantly increased the risk of alveolar hemorrhage compared to untreated controls (0.20% vs 0.025%; P=0.017).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: